TMPRSS-5 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human TMPRSS-5 (Spinesin; UniProt Q9H3S3), expressed in HEK293 cells. Suitable for serine protease activity assays, inhibitor screening, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-TMPRSS5

In stock

SKU
REC-TMPRSS5
$498.00

Target Overview

TMPRSS-5 (Transmembrane Protease Serine 5, also known as Spinesin) is a type II transmembrane serine protease encoded by the TMPRSS5 gene and catalogued under UniProt accession Q9H3S3. The full-length human protein spans 457 amino acids and is anchored at the cell membrane. Like other members of the TMPRSS family, TMPRSS-5 carries a trypsin-like serine protease domain (EC 3.4.21.-) and is predicted to mediate extracellular proteolytic events, with reported roles in auditory function and cochlear biology. This recombinant form is produced in HEK293 cells, a mammalian expression system that supports the post-translational modifications — glycosylation in particular — relevant to the native protein's folding and enzymatic behaviour. HEK293-derived material is generally preferred over bacterial or insect-cell expression for transmembrane serine proteases when correct disulfide bond topology and glycan patterning are required for functional studies. Researchers use this recombinant principally in three contexts: (1) serine protease activity assays using fluorogenic or chromogenic peptide substrates to characterise catalytic parameters and screen small-molecule inhibitors; (2) inhibitor IC50 determination and selectivity profiling against the TMPRSS family; and (3) antibody validation, where a defined, soluble antigen is used as a positive control in Western blot or ELISA to confirm antibody specificity. Researchers requiring a matched antibody reagent for the latter purpose can pair this recombinant with Triple Point Biologics antibody RP-TMPRSS5, validated for Western blot against human TMPRSS-5. The recombinant is also suited as a standard in quantitative proteomics workflows and as a binding partner in protein–protein interaction studies investigating TMPRSS family substrate recognition.

Background

TMPRSS-5 is a member of the type II transmembrane serine protease (TTSP) family, a group of cell-surface proteases characterised by an N-terminal transmembrane anchor, a stem region containing various adhesion and regulatory domains, and a C-terminal trypsin-like catalytic domain. The gene was originally identified and named "Spinesin" based on its expression in the spinal cord and inner ear, where it is thought to participate in proteolytic processing relevant to hearing. Loss-of-function studies in model systems implicate TMPRSS-5 in cochlear function, making it a subject of interest in auditory biology research. Beyond its characterised role in the inner ear, TMPRSS-5 has attracted broader attention through large-scale human genetic and proteomic studies. Chen et al. (2022) applied systematic Mendelian randomization across the human plasma proteome to identify potential therapeutic targets for stroke, with TMPRSS-5 among the protein targets examined in that proteome-wide framework (PMID: 36253349). Subsequent work by Yao et al. (2025) in a proteome-wide genetic study spanning East Asian and European populations further investigated plasma proteomic targets for ischemic stroke, reinforcing interest in circulating TMPRSS-5 levels as a research variable (PMID: 40304040). Separately, circulating TMPRSS-5 has been examined in the context of diabetic neuropathy, where Ponirakis et al. (2026) reported associations between proteomic markers, including TMPRSS-5, and measures of small and large fiber neuropathy in type 2 diabetes (PMID: 41886839). Plasma TMPRSS-5 has additionally appeared in multi-gene signature studies of hypertensive intracerebral hemorrhage (PMID: 42218946) and phenome-wide copy-number-variant analyses in large biobank cohorts (PMID: 41639462). Collectively, this body of published work positions TMPRSS-5 as a research target investigated in the context of cerebrovascular disease, peripheral neuropathy, and auditory function — fields where the recombinant protein supports mechanistic in-vitro studies, serves as a calibrant for plasma proteomics assays, and provides a defined antigen for antibody characterisation. Researchers generating or validating anti-TMPRSS5 antibodies for use in these disease-model contexts may pair this recombinant with the matched Triple Point Biologics antibody (RP-TMPRSS5), which has been validated for Western blot on human samples, with predicted cross-reactivity to monkey.

Applications

  • Fluorogenic peptide substrate cleavage assay to measure serine protease catalytic activity (kcat/Km determination)
  • Small-molecule inhibitor IC50 screening and selectivity profiling against TMPRSS family members
  • Positive control antigen in Western blot to confirm anti-TMPRSS5 antibody specificity (pairs with RP-TMPRSS5)
  • ELISA standard curve preparation for quantification of TMPRSS-5 in biological samples
  • Protein–protein interaction studies examining TMPRSS-5 substrate or co-factor binding by SPR or co-immunoprecipitation
  • Calibration standard for targeted mass spectrometry (SRM/PRM) quantification of plasma TMPRSS-5
  • Coating antigen for immunisation quality control and hybridoma screening in anti-TMPRSS5 antibody development

References

  1. Gao Z et al. Identification and multicenter validation of a 4-gene plasma signature for early recognition and risk assessment in hypertensive intracerebral hemorrhage. Genomics. 2026. doi:10.1016/j.ygeno.2026.111268 PMID: 42218946
  2. Ponirakis G et al. Circulating proteomic markers are associated with measures of small and large fiber neuropathy and symptoms in type 2 diabetes. J Diabetes Complications. 2026. doi:10.1016/j.jdiacomp.2026.109313 PMID: 41886839
  3. Zou XZ et al. Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes. Nature. 2026. doi:10.1038/s41586-025-10087-x PMID: 41639462
  4. Yao P et al. Proteome-Wide Genetic Study in East Asians and Europeans Identified Multiple Therapeutic Targets for Ischemic Stroke. Stroke. 2025. doi:10.1161/STROKEAHA.125.050982 PMID: 40304040
  5. Chen L et al. Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for stroke. Nat Commun. 2022. doi:10.1038/s41467-022-33675-1 PMID: 36253349

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type II transmembrane serine protease; cell surface

Frequently Asked Questions

What is the expected molecular weight of recombinant TMPRSS-5 on SDS-PAGE or Western blot?

The full-length human TMPRSS-5 protein is 457 amino acids, giving a predicted unmodified MW of ~51 kDa. However, because this recombinant is expressed in HEK293 cells, N-linked glycosylation adds appreciable mass — expect a diffuse band running at approximately 55–65 kDa under denaturing, reducing conditions. The smearing is characteristic of heterogeneous glycosylation and does not indicate degradation. If you treat the protein with PNGase F prior to SDS-PAGE, the band sharpens and migrates closer to the predicted 51 kDa backbone, which can be a useful glycosylation control in your experiment.

Is recombinant TMPRSS-5 full-length or a processed/truncated fragment, and does it include the transmembrane domain?

The recombinant TMPRSS-5 supplied here corresponds to the extracellular protease-competent region of the protein and does not include the N-terminal transmembrane anchor. Retaining the transmembrane domain in a soluble recombinant format would result in aggregation-prone material incompatible with standard solution-phase assays. The expressed fragment encompasses the serine protease domain and associated SRCR and low-density lipoprotein receptor domains, preserving the active-site triad (His, Asp, Ser) geometry required for trypsin-like catalytic activity. This is the form relevant to most substrate cleavage and inhibitor studies.

What substrates can I use to measure TMPRSS-5 serine protease activity in a fluorescence assay?

TMPRSS-5 is a trypsin-like serine protease (EC 3.4.21.-) and cleaves after basic residues (Arg, Lys). The fluorogenic substrate Boc-Gln-Ala-Arg-AMC (or the simpler Boc-Val-Pro-Arg-AMC) is a practical starting point at 50–200 µM in assay buffer. Tos-Gly-Pro-Arg-AMC, widely used for other TMPRSS family members, is also compatible. Monitor AMC release at excitation 380 nm / emission 460 nm. Run a no-enzyme blank and a heat-inactivated enzyme control in parallel to confirm signal is protease-dependent rather than substrate autofluorescence.

What buffer conditions and pH are optimal for a TMPRSS-5 activity assay?

TMPRSS-5 is stored in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — a buffer compatible with direct use in activity assays, though glycerol carryover above ~2% can reduce some fluorogenic substrate signals. For kinetic assays, dilute into 50 mM HEPES pH 7.5, 150 mM NaCl, 0.01% Tween-20 (to limit surface adsorption). The protease shows trypsin-like activity across pH 7.0–8.0; avoid pH below 6.5 or above 9.0. Do not include EDTA — while TMPRSS-5 is a serine protease rather than a metalloprotease, chelators can destabilise the protein at low concentrations.

What starting concentration of recombinant TMPRSS-5 should I use for inhibitor IC50 measurements?

For IC50 determinations, titrate the enzyme first to establish a concentration that gives a linear signal over your assay window — typically 1–10 nM recombinant TMPRSS-5 with 100 µM fluorogenic substrate is a workable starting range. Keep enzyme concentration well below the Ki of your inhibitor to satisfy tight-binding assumptions (Morrison equation) if necessary. Run the inhibitor dilution series in triplicate with at least 30 min pre-incubation at room temperature before initiating with substrate. Confirm DMSO vehicle tolerance up to 1% v/v, as higher concentrations can measurably reduce serine protease activity.

How much recombinant TMPRSS-5 should I load as a Western blot positive control when validating the RP-TMPRSS5 antibody?

For Western blot positive control alongside anti-TMPRSS-5 rabbit polyclonal antibody (RP-TMPRSS5), load 50–100 ng of recombinant TMPRSS-5 per lane on a 10–12% SDS-PAGE gel. At this loading, RP-TMPRSS5 at a 1:500–1:2,000 primary antibody dilution (HRP-conjugated anti-rabbit secondary, 1:5,000–1:10,000) reliably produces a band in the 55–65 kDa region. The recombinant and RP-TMPRSS5 antibody are produced in the same laboratory from matched immunogen material, so this pairing provides a confirmed positive signal without ambiguity about epitope accessibility.

Can recombinant TMPRSS-5 be used to validate the RP-TMPRSS5 antibody for IHC or confirm antibody specificity in cell lysates?

Yes. Because REC-TMPRSS5 and RP-TMPRSS5 are produced as a matched pair, the recombinant is the most direct tool for antibody specificity confirmation. For cell lysate spike-in experiments, add 100–250 ng of recombinant TMPRSS-5 to your negative-control lysate (e.g., a TMPRSS5-knockout or low-expression cell line) and run alongside unspiked lysate — RP-TMPRSS5 should show a concentration-dependent signal only in the spiked lane. For IHC antigen retrieval validation, the recombinant can be spotted on nitrocellulose as a dot-blot control. See the RP-TMPRSS5 product page at /anti-tmprss-5-rabbit-polyclonal-antibody for validated dilution ranges.

How should I store and handle recombinant TMPRSS-5 to preserve enzymatic activity after receipt?

Upon receipt, briefly centrifuge the tube to consolidate the liquid, then aliquot into single-use volumes appropriate for your experiment before storing at -20°C. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) provides cryoprotection, but repeated freeze-thaw cycles measurably degrade serine protease activity — even two cycles can reduce specific activity by 20–40% in our internal QC monitoring. For experiments requiring several weeks of use, store working aliquots at 4°C for up to 7 days. Avoid diluting the stock below ~0.1 mg/mL without adding carrier protein (0.1% BSA) to limit adsorptive loss on tube surfaces.

Validation imagery coming soon

Western blot validation figures for REC-TMPRSS5 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →